Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease

Human Molecular Genetics

Volumn 25, Issue 13, 2016, Pages 2645-2660

  Rockenstein, Edward ^a   Clarke, Jennifer ^b   Viel, Catherine ^b   Panarello, Nicholas ^b   Treleaven, Christopher M ^b   Kim, Changyoun ^a   Spencer, Brian ^a   Adame, Anthony ^a   Park, Hyejung ^b   Dodge, James C ^b   Cheng, Seng H ^b   Shihabuddin, Lamya S ^b   Masliah, E ^a   Sardi, S Pablo ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; GLUCOSYLCERAMIDASE; KINESIN; LYSOSOME ENZYME; MYOSIN; NEURON SPECIFIC NUCLEAR PROTEIN; POSTSYNAPTIC DENSITY PROTEIN 95; SYNAPSIN I; SYNAPSIN II; SYNAPTOBREVIN 2; SYNAPTOPHYSIN; SYNAPTOTAGMIN; SYNTAXIN; ALPHA SYNUCLEIN; DOPAMINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; COGNITION; CONTROLLED STUDY; DEMENTIA; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL BEHAVIORAL TEST; FEMALE; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HYPERACTIVITY; IMMUNOCYTOCHEMISTRY; MOTOR ACTIVITY; MOUSE; MURINE MODEL; NONHUMAN; PARKINSON DISEASE; POLE TEST; TRANSGENIC MOUSE; YOUNG ADULT; ANIMAL; CEREBROSPINAL FLUID; DISEASE MODEL; DRUG EFFECTS; GAUCHER DISEASE; GENE EXPRESSION; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; COGNITION; DISEASE MODELS, ANIMAL; DOPAMINE; GAUCHER DISEASE; GENE EXPRESSION; GLUCOSYLCERAMIDASE; HUMANS; MICE; MOTOR ACTIVITY; MUTATION; PARKINSON DISEASE;

EID: 85016028593     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddw124     Document Type: Article

References (72)

1. Lang, A.E. and Lozano, A.M. (1998) Parkinson's disease. First of two parts. N. Engl. J. Med., 339, 1044-1053.
2. Sidransky, E., Nalls, M.A., Aasly, J.O., Aharon-Peretz, J., Annesi, G., Barbosa, E.R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med., 361, 1651-1661.
3. Clark, L.N., Ross, B.M., Wang, Y., Mejia-Santana, H., Harris, J., Louis, E.D., Cote, L.J., Andrews, H., Fahn, S., Waters, C., et al. (2007) Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology, 69, 1270-1277.
4. Sidransky, E. and Lopez, G. (2012) The link between the GBA gene and parkinsonism. Lancet Neurol., 11, 986-998.
5. Tsuang, D., Leverenz, J.B., Lopez, O.L., Hamilton, R.L., Bennett, D.A., Schneider, J.A., Buchman, A.S., Larson, E.B., Crane, P.K., Kaye, J.A., et al. (2012) GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology, 79, 1944-1950.
6. Beavan, M.S. and Schapira, A.H. (2013) Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Ann. Med., 45, 511-521.
7. Lesage, S., Anheim, M., Condroyer, C., Pollak, P., Durif, F., Dupuits, C., Viallet, F., Lohmann, E., Corvol, J.C., Honore, A., et al. (2010) Large-scale screening of the Gaucher's diseaserelated glucocerebrosidase gene in Europeans with Parkinson's disease. Hum. Mol. Genet., 20, 202-210.
8. Brockmann, K., Srulijes, K., Hauser, A.K., Schulte, C., Csoti, I., Gasser, T. and Berg, D. (2011) GBA-associated PD presents with nonmotor characteristics. Neurology, 77, 276-280.
9. McNeill, A., Duran, R., Proukakis, C., Bras, J., Hughes, D., Mehta, A., Hardy, J., Wood, N.W. and Schapira, A.H. (2012) Hyposmia and cognitive impairment in Gaucher disease patients and carriers. Mov. Disord., 27, 526-532.
10. Alcalay, R.N., Caccappolo, E., Mejia-Santana, H., Tang, M., Rosado, L., Orbe Reilly, M., Ruiz, D., Ross, B., Verbitsky, M., Kisselev, S., et al. (2012) Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology, 78, 1434-1440.
11. Winder-Rhodes, S.E., Evans, J.R., Ban, M., Mason, S.L., Williams-Gray, C.H., Foltynie, T., Duran, R., Mencacci, N.E., Sawcer, S.J. and Barker, R.A. (2013) Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain, 136, 392-399.
12. Zokaei, N., McNeill, A., Proukakis, C., Beavan, M., Jarman, P., Korlipara, P., Hughes, D., Mehta, A., Hu, M.T., Schapira, A.H., et al. (2014) Visual short-term memory deficits associated with GBA mutation and Parkinson's disease. Brain, 137, 2303-2311.
13. Wang, C., Cai, Y., Gu, Z., Ma, J., Zheng, Z., Tang, B.S., Xu, Y., Zhou, Y., Feng, T., Wang, T., et al. (2014) Clinical profiles of Parkinson's disease associated with common leucine-rich repeat kinase 2 and glucocerebrosidase genetic variants in Chinese individuals. Neurobiol. Aging, 35, 725 e721-e726.
14. Li, Y., Sekine, T., Funayama, M., Li, L., Yoshino, H., Nishioka, K., Tomiyama, H. and Hattori, N. (2014) Clinicogenetic study of GBA mutations in patients with familial Parkinson's disease. Neurobiol. Aging, 35, 935 e933-e938.
15. Brockmann, K., Srulijes, K., Pflederer, S., Hauser, A.K., Schulte, C., Maetzler, W., Gasser, T. and Berg, D. (2015) GBAassociated Parkinson's disease: reduced survival and more rapid progression in a prospective longitudinal study. Mov. Disord., 30, 407-411.
16. Sardi, S.P., Cheng, S.H. and Shihabuddin, L.S. (2015) Gaucherrelated synucleinopathies: the examination of sporadic neurodegeneration from a rare (disease) angle. Prog. Neurobiol., 125C, 47-62.
17. Gan-Or, Z., Giladi, N., Rozovski, U., Shifrin, C., Rosner, S., Gurevich, T., Bar-Shira, A. and Orr-Urtreger, A. (2008) Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology, 70, 2277-2283.
18. Nichols, W.C., Pankratz, N., Marek, D.K., Pauciulo, M.W., Elsaesser, V.E., Halter, C.A., Rudolph, A., Wojcieszek, J., Pfeiffer, R.F. and Foroud, T. (2009) Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology, 72, 310-316.
19. Bultron, G., Kacena, K., Pearson, D., Boxer, M., Yang, R., Sathe, S., Pastores, G. and Mistry, P.K. (2010) The risk of Parkinson's disease in type 1 Gaucher disease. J. Inherit. Metab. Dis., 33, 167-173.
20. Barrett, M.J., Giraldo, P., Capablo, J.L., Alfonso, P., Irun, P., Garcia-Rodriguez, B., Pocovi, M. and Pastores, G.M. (2013) Greater risk of parkinsonism associated with non-N370S GBA1 mutations. J. Inherit. Metab. Dis., 36, 575-580.
21. Becker, J.G., Pastores, G.M., Di Rocco, A., Ferraris, M., Graber, J.J. and Sathe, S. (2013) Parkinson's disease in patients and obligate carriers of Gaucher disease. Parkinsonism Relat. Disord., 19, 129-131.
22. Alcalay, R.N., Dinur, T., Quinn, T., Sakanaka, K., Levy, O., Waters, C., Fahn, S., Dorovski, T., Chung, W.K., Pauciulo, M., et al. (2014) Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. JAMA Neurol., 71, 752-757.
23. Gan-Or, Z., Amshalom, I., Kilarski, L.L., Bar-Shira, A., Gana-Weisz, M., Mirelman, A., Marder, K., Bressman, S., Giladi, N. and Orr-Urtreger, A. (2015) Differential effects of severe vs mild GBA mutations on Parkinson disease. Neurology, 84, 880-887.
24. Xu, Y.H., Sun, Y., Ran, H., Quinn, B., Witte, D. and Grabowski, G.A. (2010) Accumulation and distribution of alphasynuclein and ubiquitin in the CNS of Gaucher disease mouse models. Mol. Genet. Metab., 102, 436-447.
25. Cullen, V., Sardi, S.P., Ng, J., Xu, Y.H., Sun, Y., Tomlinson, J.J., Kolodziej, P., Kahn, I., Saftig, P., Woulfe, J., et al. (2011) Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alphasynuclein processing. Ann. Neurol., 69, 940-953.
26. Sardi, S.P., Clarke, J., Kinnecom, C., Tamsett, T.J., Li, L., Stanek, L.M., Passini, M.A., Grabowski, G.A., Schlossmacher, M.G., Sidman, R.L., et al. (2011) CNS expression of glucocerebrosidase corrects (alpha)-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy. Proc. Natl Acad. Sci. U S A, 108, 12101-12106.
27. Ginns, E.I., Mak, S.K., Ko, N., Karlgren, J., Akbarian, S., Chou, V.P., Guo, Y., Lim, A., Samuelsson, S., LaMarca, M.L., et al. (2014) Neuroinflammation and alpha-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction. Mol. Genet. Metab., 111, 152-162.
28. Xu, Y.H., Xu, K., Sun, Y., Liou, B., Quinn, B., Li, R.H., Xue, L., Zhang, W., Setchell, K.D., Witte, D., et al. (2014) Multiple pathogenic proteins implicated in neuronopathic Gaucher disease mice. Hum. Mol. Genet., 23, 3943-3957.
29. Fishbein, I., Kuo, Y.M., Giasson, B.I. and Nussbaum, R.L. (2014) Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation. Brain, 137, 3235-3247.
30. Sardi, S.P., Clarke, J., Viel, C., Chan, M., Tamsett, T.J., Treleaven, C.M., Bu, J., Sweet, L., Passini, M.A., Dodge, J.C., et al. (2013) Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc. Natl Acad. Sci. U S A, 110, 3537-3542.
31. Giasson, B.I., Duda, J.E., Quinn, S.M., Zhang, B., Trojanowski, J.Q. and Lee, V.M. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron, 34, 521-533.
32. Gegg, M.E., Burke, D., Heales, S.J., Cooper, J.M., Hardy, J., Wood, N.W. and Schapira, A.H. (2012) Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains. Ann. Neurol., 72, 455-463.
33. Rocha, E.M., Smith, G.A., Park, E., Cao, H., Brown, E., Hallett, P. and Isacson, O. (2015) Progressive decline of glucocerebrosidase in aging and Parkinson's disease. Ann. Clin. Transl. Neurol., 2, 433-438.
34. Deacon, R.M. (2006) Assessing nest building in mice. Nat. Protoc., 1, 1117-1119.
35. Paumier, K.L., Sukoff Rizzo, S.J., Berger, Z., Chen, Y., Gonzales, C., Kaftan, E., Li, L., Lotarski, S., Monaghan, M., Shen, W., et al. (2013) Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease. PLoS One, 8, e70274.
36. Passini, M.A., Bu, J., Roskelley, E.M., Richards, A.M., Sardi, S.P., O'Riordan, C.R., Klinger, K.W., Shihabuddin, L.S. and Cheng, S.H. (2010) CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J. Clin. Invest., 120, 1253-1264.
37. Vitner, E.B., Salomon, R., Farfel-Becker, T., Meshcheriakova, A., Ali, M., Klein, A.D., Platt, F.M., Cox, T.M. and Futerman, A.H. (2014) RIPK3 as a potential therapeutic target for Gaucher's disease. Nat. Med., 20, 204-208.
38. Farfel-Becker, T., Vitner, E.B., Kelly, S.L., Bame, J.R., Duan, J., Shinder, V., Merrill, A.H., Jr., Dobrenis, K. and Futerman, A.H. (2014) Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration. Hum. Mol. Genet., 23, 843-854.
39. Cabeza-Arvelaiz, Y., Fleming, S.M., Richter, F., Masliah, E., Chesselet, M.F. and Schiestl, R.H. (2011) Analysis of striatal transcriptome in mice overexpressing human wild-type alpha-synuclein supports synaptic dysfunction and suggests mechanisms of neuroprotection for striatal neurons. Mol. Neurodegener., 6, 83.
40. Miller, R.M., Kiser, G.L., Kaysser-Kranich, T.M., Lockner, R.J., Palaniappan, C. and Federoff, H.J. (2006) Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiol. Dis., 21, 305-313.
41. Rockenstein, E., Mallory, M., Hashimoto, M., Song, D., Shults, C.W., Lang, I. and Masliah, E. (2002) Differential neuropathological alterations in transgenic mice expressing alphasynuclein from the platelet-derived growth factor and Thy-1 promoters. J. Neurosci. Res., 68, 568-578.
42. Chesselet, M.F., Richter, F., Zhu, C., Magen, I., Watson, M.B. and Subramaniam, S.R. (2012) A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics, 9, 297-314.
43. Mazzulli, J.R., Xu, Y.H., Sun, Y., Knight, A.L., McLean, P.J., Caldwell, G.A., Sidransky, E., Grabowski, G.A. and Krainc, D. (2011) Gaucher disease glucocerebrosidase and alphasynuclein form a bidirectional pathogenic loop in synucleinopathies. Cell, 146, 37-52.
44. Yap, T.L., Velayati, A., Sidransky, E. and Lee, J.C. (2013) Membrane-bound alpha-synuclein interacts with glucocerebrosidase and inhibits enzyme activity. Mol. Genet. Metab., 108, 56-64.
45. Hatami, A. and Chesselet, M.F. (2015) Transgenic rodent models to study alpha-synuclein pathogenesis, with a focus on cognitive deficits. Curr. Topics Behav. Neurosci., 22, 303-330.
46. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840.
47. Amschl, D., Neddens, J., Havas, D., Flunkert, S., Rabl, R., Romer, H., Rockenstein, E., Masliah, E., Windisch, M. and Hutter-Paier, B. (2013) Time course and progression of wild type alpha-synuclein accumulation in a transgenic mouse model. BMC Neuroscience, 14, 6.
48. Laguna, A., Schintu, N., Nobre, A., Alvarsson, A., Volakakis, N., Jacobsen, J.K., Gomez-Galan, M., Sopova, E., Joodmardi, E., Yoshitake, T., et al. (2015) Dopaminergic control of autophagic-lysosomal function implicates Lmx1b in Parkinson's disease. Nat. Neurosci., 18, 826-835.
49. Cheng, H.C., Ulane, C.M. and Burke, R.E. (2010) Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol., 67, 715-725.
50. Torres, G.E., Gainetdinov, R.R. and Caron, M.G. (2003) Plasma membrane monoamine transporters: structure, regulation and function. Nat. Rev. Neurosci., 4, 13-25.
51. Tolleson, C. and Claassen, D. (2012) The function of tyrosine hydroxylase in the normal and Parkinsonian brain. CNS Neurol. Disorders Drug Targets, 11, 381-386.
52. Nalls, M.A., Duran, R., Lopez, G., Kurzawa-Akanbi, M., McKeith, I.G., Chinnery, P.F., Morris, C.M., Theuns, J., Crosiers, D., Cras, P., et al. (2013) A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol., 70, 727-735.
53. Manning-Bog, A.B., Schule, B. and Langston, J.W. (2009) Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology, 30, 1127-1132.
54. Sardi, S.P., Singh, P., Cheng, S.H., Shihabuddin, L.S. and Schlossmacher, M.G. (2012) Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models. Neurodegener. Dis., 10, 195-202.
55. Alcalay, R.N., Levy, O.A., Waters, C.C., Fahn, S., Ford, B., Kuo, S.H., Mazzoni, P., Pauciulo, M.W., Nichols, W.C., Gan-Or, Z., et al. (2015) Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. Brain, 138, 2648-2658.
56. Schondorf, D.C., Aureli, M., McAllister, F.E., Hindley, C.J., Mayer, F., Schmid, B., Sardi, S.P., Valsecchi, M., Hoffmann, S., Schwarz, L.K., et al. (2014) iPSC-derived neurons from GBA1-associated Parkinson's disease patients show autophagic defects and impaired calcium homeostasis. Nat. Commun, 5, 4028.
57. Sillence, D.J., Puri, V., Marks, D.L., Butters, T.D., Dwek, R.A., Pagano, R.E. and Platt, F.M. (2002) Glucosylceramide modulates membrane traffic along the endocytic pathway. J. Lipid Res., 43, 1837-1845.
58. Awad, O., Sarkar, C., Panicker, L.M., Miller, D., Zeng, X., Sgambato, J.A., Lipinski, M.M. and Feldman, R.A. (2015) Altered TFEB-mediated lysosomal biogenesis in Gaucher disease iPSC-derived neuronal cells. Hum. Mol. Genet., 24, 5775-5788.
59. Kilpatrick, B.S., Magalhaes, J., Beavan, M.S., McNeill, A., Gegg, M.E., Cleeter, M.W., Bloor-Young, D., Churchill, G.C., Duchen, M.R., Schapira, A.H., et al. (2016) Endoplasmic reticulum and lysosomal Ca (2+) stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts. Cell Calcium, 59, 12-20.
60. Bendor, J.T., Logan, T.P. and Edwards, R.H. (2013) The function of alpha-synuclein. Neuron, 79, 1044-1066.
61. Galvagnion, C., Buell, A.K., Meisl, G., Michaels, T.C., Vendruscolo, M., Knowles, T.P. and Dobson, C.M. (2015) Lipid vesicles trigger alpha-synuclein aggregation by stimulating primary nucleation. Nat. Chem. Biol., 11, 229-234.
62. Beavan, M., McNeill, A., Proukakis, C., Hughes, D.A., Mehta, A. and Schapira, A.H. (2015) Evolution of prodromal clinical markers of parkinson disease in a GBA mutation-positive cohort. JAMA Neurol., 72, 201-208.
63. Bekinschtein, P., Cammarota, M. and Medina, J.H. (2014) BDNF and memory processing. Neuropharmacology, 76(Pt C), 677-683.
64. Vairo, F., Sperb-Ludwig, F., Wilke, M., Michellin-Tirelli, K., Netto, C., Neto, E.C. and Doederlein Schwartz, I.V. (2015) Brain-derived neurotrophic factor expression increases after enzyme replacement therapy in Gaucher disease. J. Neuroimmunol., 278, 190-193.
65. Martinez-Vicente, M. and Cuervo, A.M. (2007) Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet. Neurol., 6, 352-361.
66. Cremades, N., Cohen, S.I., Deas, E., Abramov, A.Y., Chen, A.Y., Orte, A., Sandal, M., Clarke, R.W., Dunne, P., Aprile, F.A., et al. (2012) Direct observation of the interconversion of normal and toxic forms of alpha-synuclein. Cell, 149, 1048-1059.
67. Farfel-Becker, T., Vitner, E.B. and Futerman, A.H. (2011) Animal models for Gaucher disease research. Dis. Model Mech., 4, 746-752.
68. Matsuura, K., Kabuto, H., Makino, H. and Ogawa, N. (1997) Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J. Neurosci. Methods, 73, 45-48.
69. Fleming, S.M., Salcedo, J., Fernagut, P.O., Rockenstein, E., Masliah, E., Levine, M.S. and Chesselet, M.F. (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J. Neurosci., 24, 9434-9440.
70. Stanek, L.M., Sardi, S.P., Mastis, B., Richards, A.R., Treleaven, C.M., Taksir, T., Misra, K., Cheng, S.H. and Shihabuddin, L.S. (2014) Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. Hum. Gene Ther., 25, 461-474.
71. Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A. and Mucke, L. (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science, 287, 1265-1269.
72. Masliah, E., Rockenstein, E., Mante, M., Crews, L., Spencer, B., Adame, A., Patrick, C., Trejo, M., Ubhi, K., Rohn, T.T., et al. (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One, 6, e19338.